Rutin Tetranitrate | 1005139-39-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: Rutin Tetranitrate
• 英文别名: [4-[5,7-dinitrooxy-4-oxo-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-2-yl]-2-nitrooxyphenyl] nitrate
• CAS: 1005139-39-8
• 化学式: C₂₇H₂₆N₄O₂₄
• 分子量: 790.516
• InChiKey: HDEMNVQXXAVHIM-NVPNHPEKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  55
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  405
• 氢给体数：
  6
• 氢受体数：
  24

反应信息

• 作为产物：
  描述：

  quercetin-3-O-rhamnopyranosyl-(1→6)-glucopyranoside 以 四氢呋喃 为溶剂， 生成 Rutin Tetranitrate
  参考文献：
  名称：

  Nitric oxide donating derivatives for the treatment of cardiovascular disorders

  摘要：

  本发明提供了由stilbenes、多酚和类黄酮的亚硝酸盐衍生物组成的化合物，以及它们的使用方法，用于治疗患有高胆固醇血症、血管氧化应激和内皮功能障碍的患者。

  公开号：

  US20050080024A1

文献信息

• Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
  申请人：Tucker Joseph

  公开号：US20050080021A1

  公开（公告）日：2005-04-14

  Compounds and methods are provided for treating patients suffering from any of hypercholesterolemia, vascular oxidative stress and endothelial dysfunction.

  提供了用于治疗患有高胆固醇血症、血管氧化应激和内皮功能障碍的患者的化合物和方法。
• TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT
  申请人：RESVERLOGIX CORP.

  公开号：EP1670485A1

  公开（公告）日：2006-06-21
• NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS
  申请人：RESVERLOGIX CORP.

  公开号：EP1670484A1

  公开（公告）日：2006-06-21
• EP1670485A4
  申请人：——

  公开号：EP1670485A4

  公开（公告）日：2009-03-11
• Treatment of diseases associated with the egr-1 enhancer element
  申请人：Wong Norman

  公开号：US20070099826A1

  公开（公告）日：2007-05-03

  Compounds and methods are provided for treating patients suffering from health condition associated with an expression state of a gene such as fertility disorders, cancer, proliferative diseases, vascular diseases, wounds requiring therapeutic intervention, inflammation, and pulmonary disorders by administering to said patient a compound capable of modulating egr-1 and/or an egr-1 response element consensus sequence thereby altering the expression state of said gene. Also described are new methods for screening compounds to identify effectors of egr-1 and/or egr-1 consensus sequence elements and methods for treating patients by administering such effectors to modulate egr-1 and/or egr-1 consensus sequences to thereby modify expression of genes associated therewith to in turn treat diseases or other physiological conditions associated with such gene expression.